Abstract
Background: Angiotensin-converting enzyme 2 (ACE2), a primary component of the vasoprotective axis in the renin-angiotensin system (RAS), has recently been found to have regulatory actions in hypoxic pulmonary hypertension and monocrotaline-induced pulmonary hypertension. We explored the hypothesis that the level of ACE2 protein contents may be decreased in patients with pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD). Objective: We observed the serum ACE2 protein contents in patients with PAH due to CHD (CHD-PAH), and investigated their correlation with mean pulmonary arterial pressure (mPAP). Methods: One hundred and four patients with CHD and 33 normal control patients (group A) were involved in the research. The patients with CHD were divided into 55 cases of nonpulmonary hypertension (group B), 25 cases of mild to moderate pulmonary hypertension (group C) and 24 cases of severe pulmonary hypertension (group D). The serum level of ACE2 protein contents were detected by enzyme-linked immunosorbent assay (ELISA), and the relationship between these contents and mPAP were analyzed. Results: ACE2 protein contents significantly declined as mPAP increased. The mPAP was negatively correlated with the level of ACE2 protein contents. Conclusions: These results demonstrated that ACE2 may play an important regulatory role in CHD-PAH.
Journal Section:
Editor's choice
References
1.
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 suppl):S43-S54.
2.
Trojnarska O, Plaskota K: Therapeutic methods used in patients with Eisenmenger syndrome. Cardiol J 2009;16:500-506.
[PubMed]
3.
Vaz-Silva I, Carneiro MM, Ferreria MC, Pinheiro SV, Silva DA, Silva-Fillo AL, Witz CA, Reis AM, Santos RA, Reis FM: The vasoactive peptide angiotensin-(1-7), its receptor Mas and the angiotensin-converting enzyme type 2 are expressed in the human endothelium. Reprod Sci 2009;16:247-256.
[PubMed]
4.
Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM: Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J 2010;74:405-410.
[PubMed]
5.
Raizada MK, Ferreira AJ: ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007;50:112-119.
[PubMed]
6.
Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, Raizada MK: Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:1048-1054.
[PubMed]
7.
Shenoy V, Qi Y, Katovich MJ, Raizada MK: ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol 2011;11:150-155.
[PubMed]
8.
Johnson JA, West J, Maynard KB, Hemnes AR: ACE2 improves right ventricular function in a pressure overload model. PLoS One 2011;6:e20828.
[PubMed]
9.
Li G, Xu YL, Ling F, Liu AJ, Wang D, Wang Q, Liu YL: Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels. Chin Med J (Engl) 2012;125:1381-1388.
[PubMed]
10.
Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, Yuan L, Bradford CN, Shenoy V, Oh SP, Katovich MJ, Raizada MK: Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 2009;54:365-371.
[PubMed]
11.
Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Díez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, Venugopal CS, Francis J, Reudelhuber T, Santos RA, Patel JM, Raizada MK, Katovich MJ: The ACE2/Ang-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010;182:1065-1072.
[PubMed]
12.
Kleinsasser A, Pircher I, Treml B, Schwienbacher M, Schuster M, Janzek E, Loibner H, Penninger JM, Loeckinger A: Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia. Wilderness Environ Med 2012;23:24-30.
[PubMed]
13.
Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, Schuster M, Janzek E, Loibner H, Penninger J, Loeckinger A: Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide induced lung injury in piglets. Crit Care Med 2010;38:596-601.
[PubMed]
14.
Rondelet B, Kerbaul F, Van Beneden R, Hubloue I, Huez S, Fesler P, Remmelink M, Brimioulle S, Salmon I, Naeije R: Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2005;289:H2319-H2324.
[PubMed]
15.
Farber HW, Loscalzo J: Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-1665.
[PubMed]
16.
Smadja DM, Gaussem P, Mauge L, Israel-Biet D, Dignat-George F, Peyrard S, Agnoletti G, Vouhe PR, Bonnet D, Levy M: Circulating endothelial cells: a newcandidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009;119:374-381.
[PubMed]
17.
Schrier RW, Bansal S: Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol 2008;3:1232-1237.
[PubMed]
18.
Hayashi N, Yamamoto K, Ohishi M, Tatara Y, Takeya Y, Shiota A, Oguro R, Iwamoto Y, Takeda M, Rakugi H: The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells. Hypertens Res 2010;33:1182-1185.
[PubMed]
19.
Li J, Gao J, Xu YP, Zhou TL, Jin YY, Lou JN: Expression of severe acute respiratory syndrome coronavirus receptors, ACE2 and CD209L in different organ derived microvascular endothelial cells. Zhonghua Yi Xue Za Zhi 2007;87:833-837.
[PubMed]
© 2013 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2013
You do not currently have access to this content.
